The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19
Status:
Recruiting
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg
versus placebo once daily administration with standard of care therapy for 14 days (maximum
up to 21 days) in patients with moderate COVID-19.